Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Product news (15 November 2008)

New medicine: Bridion / SPC changes: Humira / Prescription products: Xamiol / Discontinued products: All-Flex/Gyno Daktarin; Dynepo; LifeScan test strips

New Medicine

Bridion

Composition: Sugammadex sodium.

Presentation: Solution for injection.

Action: Modified gamma cyclodextrin, a selective relaxant binding agent.

Indications: Reversal of neuromuscular blockade induced by rocuronium or vecuronium. In children and adolescents Bridion is only recommended for routine reversal of rocuronium induced blockade.

Dosage: For routine reversal in adults, 4mg/kg is recommended if recovery has reached at least one to two post-tetanic counts following rocuronium- or vecuronium-induced blockade.

A dose of 2mg/kg is recommended if spontaneous recovery has occurred up to at least the reappearance of T2 following blockade induced by rocuronium or vecuronium.

For immediate reversal of rocuronium-induced blockade a dose of 16mg/kg is recommended.

If blockade recurs postoperatively after an initial dose of 2mg/kg or 4mg/kg, a repeat dose of 4mg/kg is recommended.

For routine reversal of rocronium-induced blockade in children and adolescents 2mg/kg is recommended.

Immediate reversal is not recommended.

Precautions: Bridion is not recommended in patients with severe renal impairment.

Ventilatory support is mandatory for patients until adequate spontaneous respiration is restored following reversal of neuromuscular block.

Toremifene, flucloxacillin and fusidic acid have the potential to affect the efficacy of Bridion because they may cause some displacement of rocuronium or vecuronium from the complex with Bridion.

Bridion has the potential to reduce the efficacy of hormonal contraceptives.

The administration of a bolus dose of Bridion should be considered to be equivalent to one missed daily dose of oral contraceptive.

Side effects: Very common (=1/10) dysgeusia. Common (=1/100 to <1/10) anaesthetic complication.

Legal category: POM.

Net price:
10 x 200mg/2ml, £596.40
10 x 500mg/5ml, £1,491

Contact details: Schering-Plough Ltd, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW (tel 01707 363636).

 

SPC changes

Humira

Humira (adalimumab; Abbott) is now indicated — in combination with methotrexate, or as monotherapy where methotrexate is not tolerated or where combination therapy is inappropriate — for the treatment of active polyarticular idiopathic arthritis in adolescents aged 13 to 17 years who have inadequate response to one or more disease-modifying antirheumatic drugs.

The updated summary of product characteristics recommends a single dose of 40mg fortnightly via subcutaneous injection, and states that a response should be achieved within 12 weeks of initiation of treatment.

The SPC recommends that patients treated under the new indication be brought up to date with immunisations, in agreement with current immunisation guidelines, before initiating adalimumab therapy.

The SPC now states that adalimumab may have a minor influence on the ability to drive or to operate machinery.

 

Prescription products

Xamiol

Xamiol (calcipotriol 50µg/betamethasone dipropionate 0.5mg) gel is now available from LEO Pharma.

Net price: 1 x 60g, £36.50

Legal category: POM

 

Discontinued products

All-Flex/Gyno Daktarin

Janssen-Cilag will discontinue All-Flex latex diaphragms 65mm, 70mm, 75mm and 80mm, and Gyno Daktarin pessaries 14 x 100mg in December 2008.

Further information on 01494 567444.

Dynepo

Shire will discontinue Dynepo (epoetin delta) from 31 January 2009.

Further information on 0800 055 6614.

LifeScan test strips

LifeScan will discontinue OneTouch and PocketScan test strips in December, following the discontinuation in 2002 of their corresponding blood glucose meters. Further information on 01494 658750.

Users of the discontinued OneTouch Basic, OneTouch Profile, OneTouch II and PocketScan blood glucose meters can contact LifeScan customer care on 0800 028 8039 to arrange a free meter upgrade.

Citation: The Pharmaceutical Journal URI: 10039136

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Popular Medicines

    Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £22.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.